Arthritis drug restores 100% of hair on some patients with severe alopecia in global trial
A global trial has shown promising results for patients with severe alopecia areata, an autoimmune disease causing hair loss. Upadacitinib, a once-daily oral medication originally approved for arthritis, has demonstrated the ability to restore 100% of hair on some participants.

Briefing Summary
AI-generatedA global trial has shown promising results for patients with severe alopecia areata, an autoimmune disease causing hair loss. Upadacitinib, a once-daily oral medication originally approved for arthritis, has demonstrated the ability to restore 100% of hair on some participants. Scientists hypothesized that the drug, which calms inflammation by suppressing immune overreactions, could also target the immune system's attack on hair follicles in alopecia areata. This trial offers new hope as there have been no reliably effective treatments for the condition until now.
Article analysis
Model · rule-basedKey claims
4 extractedUpadacitinib was previously approved to treat inflammation in various forms of arthritis.
Alopecia areata is an autoimmune disease where the immune system attacks hair follicles, causing hair loss.
An arthritis drug, upadacitinib, has shown promise in restoring 100% of hair on some patients with severe alopecia areata in a global trial.
Scientists suspected upadacitinib might help alopecia areata by calming immune overreactions that destroy hair follicles.